New Non Insulin Drugs for Management of Type2DM

Slides:



Advertisements
Similar presentations
Katee Lira, PharmD PGY2 Ambulatory Care Pharmacy Resident
Advertisements

JARDIANCE: Newly Approved Drug to Lower HbA1C in Type-2 diabetes
The New HbA1c HbA1c – DCCT (%) HbA1c – IFFC (mmol/mol)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.
Farxiga™ - Dapagliflozin
Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.
Oral Medications to Treat Type 2 Diabetes
ADVANCE IN TREATMENT OF TYPE 2 D.M. BY DR : RAMYAHMED SAMY M.D. LECTURER OF INTERNAL MEDICINE BANHA UNIVERSITY
Barriers to Diabetes Control Mark E. Molitch, MD.
LONG TERM BENEFITS OF ORAL AGENTS
Drugs used in Diabetes Dr Sally Hudson. BIGUANIDES reduce output of glucose from the liver and enhances uptake and use of glucose by muscle cells ExampleADVANTAGESDISADVANTAGESCOSTCaution.
Diabetes in the 21 st Century 2010 Update. American Diabetes Association 2010 Guidelines – Diagnostic Criteria A1C > or = 6.5% is included as diagnostic.
Criteria for the diagnosis of DM Symptoms of diabetes plus random blood glucose concentration ≥ 200 mg/dl OR FPG ≥ 126 mg/dl OR Two –hour plasma glucose.
oral hypoglycemic agents
Oral Hypoglycemic Drugs
DRUGHYPOGLYCE MIA RISK ~A1C REDUCTI ON WEIGH T CHANG E ADVANTAGESDISADVANTAGES/ SIDE EFFECTS METFOR MIN No1.0 – 2.0%LOSSDecreased CV events and mortality;
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Type 2 Diabetes Across Generations: From Pathophysiology to Prevention and Management Nolan, Christopher J., Damm, Peter, Prentki, Marc Management of Type.
Saxenda (Liraglutide) SAMUEL GYAWU-AMOATENG. Indication & Approval  Saxenda, is FDA approved as a treatment option for chronic weight management in addition.
Treatment Advances in Type 2 Diabetes Panhandle Nurse Practitioner Symposium April 11, 2015 Dr. Caleb Kim.
A New Modality for Treating Type 2 Diabetes
MARGARITA SIANOSYAN, DOCTOR OF PHARMACY CANDIDATE, LECOM COLLEGE OF PHARMACY GLP-1 Analogs and Lifestyle Modifications.
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.
Amori, R. E. et al. JAMA 2007;298: Efficacy and Safety of Incretin Therapy in Type 2 Diabetes Systematic Review and Meta-analysis 亀田総合病院 1 年目初期研修医.
A Critical Analysis of the Clinical Use of Incretin-Based Therapies The benefits by far outweigh the potential risks Featured Article: Diabetes Care Volume.
The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes
Type 2 diabetes treatment: Old and New Emily Szmuilowicz, MD, MS Assistant Professor of Medicine Division of Endocrinology Northwestern University.
New Medications for Diabetes
Oral hypoglycemic drugs
Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.
Mania Radfar Pharm.D. Novel oral antidiabetic agents.
Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
GLP-1 agonists Ian Gallen Consultant Community Diabetologist
A Tale of New Drugs Rebecca Nick-Dart, PharmD, BCPS Clinical Pharmacy Specialist
A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Clerk 陳威任.
Adlyxin® - Lixisenatide
Medications Used in the Treatment of Diabetes Mellitus
Drugs for Type 2 Diabetes – where next after metformin ?
Diabetes Learning Event 7th October 2016
Stephen N. Davis, MBBS, FRCP, MACP
Dulaglutide Drugbank ID : DB09045.
Shared Decision Making and the Medical Treatment of Type 2 Diabetes
Objective 2 Discuss recent data, guidelines, and counseling points pertaining to the older adults with diabetes.
GLP-1 Agonist:When to start ?
Antihyperglycemic Agents and Renal Function
6.Fat- increased lipolysis, inc FFA
Neal B, et al. Diabetes Care 2015;38:403–411
Harsharan Pal Singh1*, Ishpreet Kaur2 , Gunjan Sharma1
Therapeutics Tutoring
Diabetes 2017 & Into The Future
GLP-1 Agonist and SGLT-2 Inhibitor Monotherapy Trial Results (handout)
Cycloset®A Dopamine Receptor Agonist Cycloset® -Bromocriptine: Safety Trial: Post Hoc Analysis of Cumulative Percent MACE Endpoint Bromocriptine (Parlodel)
Empagliflozin (Jardiance®)
oral hypoglycemic agents
Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
DM management Dr.Duaa Hiasat.
IRIS Trial Insulin Resistance Intervention after Stroke.
Rezvan Salehidoost, M.D. Endocrinologist
eGFR ‘cut-offs’ for glucose lowering therapies
DM management Dr.Duaa Hiasat.
Oral hypoglycemics Jennifer R Marks, MD.
Renal licences of commonly used anti-diabetes drugs
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.
Presentation transcript:

New Non Insulin Drugs for Management of Type2DM Muhammad Mudassar Amin, MD. Cameron Regional Medical Center.

Disclosure I have no conflict of interest in regards to this presentation.

Contents 1) What is DM2 2) consensus statement by AACE and ACE about DM2 management 3) Glucose homeostasis 4) GLP 1 Agonists 5) DPP4 inhibitors 6) SGLT2 Inhibitors 7) Bromocriptine QR 8) Amylin mimetics (Pramlinitide) 9) AACE and ACE guidelines 10) References 11) Q & A

What is DM2 According to ADA and WHO; An asymptomatic individual with any of the following fasting plasma glucose values ≥126 mg/dL OR two-hours plasma glucose value of ≥200 mg/dL during an oral glucose tolerance test (OGTT); OR A1C values ≥6.5 percent; OR A patient with classic symptoms of hyperglycemia, a random plasma glucose ≥200 mg/dl. Underlying mechanisms Insulin resistance (Environmental/Obesity) and Impaired insulin secretion (genetics)

CONSENSUS STATEMENT BY THE AACE AND ACE ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2016 EXECUTIVE SUMMARY 1) Lifestyle optimization is essential for all patients with diabetes 2) The HbA1C target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia , patient motivation, and adherence. An A1C level of ≤6.5% is considered optimal if it can be achieved in a safe and affordable manner.

3)The choice of diabetes therapies must be individualized based on attributes specific to both patients and the medications. Medication attributes that affect this choice include antihyperglycemic efficacy, mechanism of action, risk of inducing hypoglycemia, risk of weight gain, ease of use, likely adherence, cost, and safety in heart, kidney, or liver disease. 4) Minimizing risk of hypoglycemia is a priority. 5) Minimizing risk of weight gain is a priority. 6) Combination therapy is usually required and should involve agents with complementary mechanisms of action. 7) Comprehensive management includes lipid and BP therapies and treatment of related comorbidities.

Drug treatment of DM2 ACP 11/2012

Glucose Homeostasis GLP-1 is one of a family of naturally occurring gut hormones that is released in the setting of a meal, but not with intravenous carbohydrate, and stimulates insulin synthesis and secretion..

Glucose Homeostasis Orally consumed carbohydrates, proteins and lipids induce secretion of GLP 1 from intestinal L cells. However, GLP1 mediated insulin secretion from Beta cells is only observed in the presence of elevated glucose levels. The activity of GLP1 and its receptor agonists is self limiting, ceasing when blood glucose levels fall in response to secreted insulin. Exogenous insulin and Sulfonylurea based therapies, continue to act even after an ideal glucose concentration is achieved and hence can cause over-correction and hypoglycemia.

Glucagon-like peptide-1 receptor agonists (GLP 1 Receptor Agonists) GLP-1 receptor agonists reproduce or enhance the actions of the naturally occurring peptide GLP-1. Synthetic GLP-1 receptor agonists are resistant to degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and therefore have a longer half-life, facilitating clinical use. They bind to the GLP-1 receptor and stimulate glucose-dependent insulin release from the pancreatic islets.

GLP 1 Receptors Agonists; Clinical Use 1) They can be used in combination with metformin (and/or another oral agent), when weight loss or avoidance of hypoglycemia is a primary consideration. 2) They are not considered as initial therapy for the majority of patients with type 2 diabetes. 3) Among GLP-1 receptor agonists, long- rather than short-acting agents should be preferred primarily due to patient convenience. 4) GLP-1 receptor agonists generally should not be combined with DPP-4 inhibitors, as there does not appear to be additive effect on glucose lowering

Available GLP 1 Receptor Agonists Generic Name Brand Name Frequency of administration Dosing Liraglutide Victoza SQ Daily 0.6mg-1.8mg Exenatide Byetta SQ BID 5mcg-10mcg Exenatide XR Bydureon SQ weekly 2mg Albiglutide Tanzeum 30-50mg Dulaglutide Trulicity 0.75-1.5mg Glycemic Efficacy: In comparison with placebo, GLP-1 receptor agonists reduced glycated hemoglobin (A1C) by approximately 1 percentage point.

GLP 1 RA; Systemic effects Hypoglycemia Neutral Weight loss NAFLD benefit Mild CHF Hepatic Impairment No dosage adjustment necessary Renal Impairment No dosage adjustment necessary except Exenatide is contraindicated with CrCl<30mg/ml. GI Symptoms Moderate

GLP RA; Adverse effects 1) Primarily GI, Nausea, Vomiting. Nausea more common with exenatide once weekly. 2) Hypoglycemia rare (usually when taken with other hypoglycemic) 3) Pancreatitis (If patient develops pancreatitis, don’t restart and don’t initiate if there is h/o pancreatitis) 4) Injection site reactions more common with exenatide once weekly Avoid use if there is personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B

DPP4 Inhibitors DPP-4 inhibitors are a class of oral diabetes drugs that inhibit the enzyme DPP-4. DPP-4 is a ubiquitous enzyme expressed on the surface of most cell types that deactivates GIP and GLP-1; therefore, its inhibition could potentially affect glucose regulation through multiple effects. However, DPP-4 inhibitors have a modest effect on GLP-1 levels, compared with giving GLP-1 agonists.

DPP4 Inhibitors; Indication/Clinical Use 1) Used as add-on drug for patients who are inadequately controlled on metformin, a TZD, or a SU. 2) Used as monotherapy in patients who are intolerant of or have contraindications to metformin, SU, or TZDs, such as patients with CKD or who are at high risk for hypoglycemia. 3) They are not considered as initial therapy for the majority of patients with type 2 diabetes.

Available DPP4 inhibitors Generic Name Brand Name Frequency of administration dosing Sitagliptin Januvia Oral Daily 25mg, 50mg, 100mg Saxagliptin Onglyza 2.5mg, 5mg Linagliptin Tradjenta 5mg Alogliptin Nesina 6.25mg, 12.5mg, 25mg Sitagliptin/Metformin Janumet 50/500, 50/1000 Saxagliptin/Metformin Komboglyze XR 2.5/1000, 5/500, 5/1000 Linagliptin/Metformin Jentadueto 2.5/500, 2.5/850, 2.5/1000 Glycemic efficacy: In comparison with placebo, DPP4 Inhibitors reduced glycated hemoglobin (A1C) by approximately 0.52-0.74%.

DPP4 Inhibitors, Systemic Effects Hypoglycemia Neutral Weight NAFLD benefit CHF Hepatic Impairment Usually no dose adjustment necessary Renal Impairment Dose adjustment necessary based on Cr Clearance GI Symptoms

DPP4 Inhibitors; Adverse Effects Generally are tolerated very well. . Commonly reported side effects include headache, nasopharyngitis, and upper respiratory symptoms. Acute pancreatitis has been reported in association with DPP-4 inhibitors. At present, there is insufficient data to know if there is a causal relationship. DPP-4 inhibitors should be discontinued in patients who develop pancreatitis. DPP-4 inhibitors should not be initiated in a patient with a history of pancreatitis.

Glucose Homeostasis in Kidneys In people without diabetes, about 180 g of glucose is filtered daily by the renal glomeruli, and is then reabsorbed in the proximal convoluted tubule (PCT). SGLT2 (Sodium Glucose Co-Transporter 2) expressed in proximal tubule mediates reabsorption of about 90% of filtered glucose load.

SGLT2 Inhibitors The SGLT2 is expressed in the proximal tubule and mediates reabsorption of approximately 90 percent of the filtered glucose load. SGLT2 inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes.

SGLT2 Inhibitors; Clinical Use Used as adjunct in patients with inadequate control on metformin and in patients who are unwilling to consider injection therapy and in whom weight gain is a significant issue. Used as an adjunct in patients with inadequate glycemic control on two oral agents (eg, metformin and SU) Used as an adjunct in patients not adequately controlled on metformin and insulin therapy, in whom GLP-1 receptor agonists are contraindicated and increasing insulin dosing would lead to weight gain SGLT2 inhibitors are not considered as initial therapy for the majority of patients with type 2 diabetes.

Available SGLT2 Inhibitors Generic Name Brand Name Frequency Of Administration Dosing Canagliflozin Invokana Oral Daily 100mg, 300mg Dapagliflozin Farxiga 5mg, 10 mg Empagliflozin Jardiance 10 mg, 25mg Glycemic efficacy: SGLT2 Inhibitors cause mean reductions in A1C compared with placebo ranging between 0.5 to 1.1 percent.

A prior history of myocardial infarction or stroke might favor choosing empagliflozin, based on the results of the empagliflozin and cardiovascular outcomes study. 7028 patients with DM2 (mean A1C 8%) and CVD were randomly assigned to empagliflozin, 10 or 25 mg, or placebo once daily. The majority of patients were taking metformin, antihypertensives, and lipid-lowering agents (equally distributed in both groups) to control blood glucose, blood pressure, and cholesterol. Approximately 48 percent of patients in each group were taking insulin. After three years, the primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in fewer patients assigned to empagliflozin than to placebo. Whether the beneficial cardiovascular effects in those with overt CVD are specific to empagliflozin, or represent a class effect of the SGLT2 inhibitors, is unknown at this time. Canagliflozin and dapagliflozin cardiovascular trials in progress.

SGLT2 Inhibitors; Systemic Effects Hypoglycemia Neutral Weight Loss NAFLD Benefit CHF Neutral; Increased LDL Hepatic Impairment No adjustment necessary Renal Impairment Dose adjustment necessary based on Cr Clearance GI Symptoms

SGLT2 Inhibitors; Side effects 2 to 4 fold increased incidence of vulvovaginal candidiasis, reported in 10 to 15 percent of women. Increase rate of urinary tract infections. May cause symptomatic hypotension especially in older patients on diuretics and ACEI2 (osmotic diuresis). "Euglycemic" (usually meaning plasma glucose <250 mg/dL) diabetic ketoacidosis has been reported in patients with type 2 diabetes taking SGLT2 inhibitors. Serum ketones should be obtained in any patient with nausea, vomiting, or malaise while taking SGLT2 inhibitors, and SGLT2 inhibitors should be discontinued if acidosis is confirmed. Renal function should be assessed prior to initiation of SGLT2 inhibitors and monitored during treatment. There have been post marketing reports of acute kidney injury.

SGLT2 Inhibitors; Cautions SGLT2 inhibitors should not be used in patients with 1) Type 2 diabetes eGFR <60 mL/min (dapagliflozin) or <45 mL/min (canagliflozin, empagliflozin) 2) Ketosis-prone type 2 diabetes They should be used with caution with medications that predispose to acute renal injury ( NSAIDs, ACE inhibitors/ARBs, diuretics) and comorbidities that might predispose to acute renal injury (hypovolemia, heart failure).

Bromocriptine QR Quick-release bromocriptine (bromocriptine-QR) (Cycloset) was approved in 2009 for treatment of type 2 diabetes. The exact anti-diabetic mechanism of action of bromocriptine-QR is unknown. The advantages of bromocriptine-QR were minimal risk of hypoglycemia, neutral effect on weight, and reassuring cardiovascular safety over 1 year of use. Common side effects include nausea, vomiting, dizziness, and headache. Randomized placebo-controlled trials showed that the mean reduction in hemoglobin A1c (HbA1c) levels by bromocriptine-QR was 0.4-0.5% when compared with placebo after 24 weeks of therapy.

Amylin Mimetics (Pramlinitide/Symlin) Amylin is hormone released from Beta cells of pancreas along with insulin after a meal. Like insulin, its completely absent in type 1 Diabetics. It 1) Slows gastric emptying 2) Promotes satiety via hypothalamic receptors. 3) Inhibits glucagon secretion Pramlinitide is analogue of Amylin. Approved by FDA for both Type 1 (30-60mcg SQ QAC) and Type 2 diabetic patients (120 mcg SQ QAC) who use prandial insulin. Cant be mixed in syringe with insulin. Common side effects include Nausea, anorexia, fatigue, abdominal pain

Where to start and Where to go

References AACE/ACE Comprehensive DM2 Management Algorithm 2017. Uptodate.com Pubmed.com NEJM.org Annals of Internal Medicine